The law strictly prohibits introducing this product into the body of humans or animals
Protocol B (Injectable + topical): 1
Specifically, observations suggest a potential reduction in neutrophil-associated responses alongside increased markers linked to vascular formation in GHK-Cu-exposed groups
[1], [2], [3], [4] A 2021 retrospective study conducted at the Institute for Hormonal Balance in Orlando, Florida, that evaluated the use of BPC 157, alone or in combination with thymosin-beta-4 (TB4), indicates in its methodology that no human clinical trials evaluating the use of BPC 157 to help with knee pain have been published (see Table 1)
How does BPC-157 differ from TB-500 or GHK-Cu
Inspect PPE before each usereplace any damaged gear immediately to ensure proper protection